Please use this identifier to cite or link to this item:
Authors: Gairing, Simon Johannes
Mangini, Chiara
Zarantonello, Lisa
Gioia, Stefania
Nielsen, Elise Jonasson
Danneberg, Sven
Lok, Anna S.
Sultanik, Philippe
Galle, Peter Robert
Labenz, Joachim
Thabut, Dominique
Marquardt, Jens Uwe
Bloom, Patricia P.
Lauridsen, Mette Munk
Montagnese, Sara
Nardelli, Silvia
Labenz, Christian
Title: Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival
Online publication date: 17-Jan-2024
Year of first publication: 2023
Language: english
Abstract: Background and aims Minimal hepatic encephalopathy (MHE) is a frequent complication in patients with liver cirrhosis. Its impact on predicting the development of overt hepatic encephalopathy (OHE) and survival has not been studied in large multicenter studies. Methods Data from patients recruited at eight centers across Europe and the United States were analyzed. MHE was detected using the psychometric hepatic encephalopathy score (PHES). A subset was also tested with the simplified animal naming test (S-ANT1). Patients were followed for OHE development and death/liver transplantation (LTx). Results A total of 1462 patients with a median model of end-stage liver disease of 11 were included (Child-Pugh (CP) stages: A 47%/B 41%/C 12%). Median follow-up time was 19 months, during which 336 (23%) patients developed an OHE episode and 464 (32%) reached the composite end point of death/LTx (369 deaths, 95 LTx). In multivariable analyses, MHE (defined by PHES) was associated with the development of OHE (subdistribution hazard ratio 1.74, p < 0.001) and poorer LTx-free survival (hazard ratio 1.53, p < 0.001) in the total cohort as well as in the subgroup of patients without a history of OHE. In subgroup analyses, MHE (defined by PHES) was associated with OHE development in patients with CP B, whereas there was no association in patients with CP A or C. In the subgroup of patients with available S-ANT1, MHE (defined by S-ANT1) was independently associated with OHE development. Combined testing (PHES+S-ANT1) was superior to single testing for predicting OHE and poorer LTx-free survival. Conclusions This large multicenter study demonstrates that screening for MHE is a useful tool for predicting OHE and poorer survival.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY-NC-ND
Information on rights of use:
Journal: Journal of internal medicine
Version of Record (VoR)
Publisher: Wiley-Blackwell
Publisher place: Oxford u.a
Issue date: 2023
ISSN: 0954-6820
Publisher DOI: 10.1111/joim.13747
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
minimal_hepatic_encephalopath-20231211095719879.pdf1.72 MBAdobe PDFView/Open